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Intracellular nicotinamide phosphoribosyltrans-
ferase (iNampt) is an essential enzyme in the
NAD biosynthetic pathway. An extracellular
form of this protein (eNampt) has been reported
to act as a cytokine named PBEF or an insulin-
mimetic hormone named visfatin, but its physi-
ological relevance remains controversial. Here
we show that eNampt does not exert insulin-
mimetic effects in vitro or in vivo but rather
exhibits robustNADbiosyntheticactivity.Haplo-
deficiency and chemical inhibition of Nampt
cause defects in NAD biosynthesis and glu-
cose-stimulated insulin secretion in pancreatic
islets in vivo and in vitro. These defects are
corrected by administration of nicotinamide
mononucleotide (NMN), a product of the Nampt
reaction. A high concentration of NMN is present
in mouse plasma, and plasma eNampt and NMN
levels are reduced in Nampt heterozygous
females. Our results demonstrate that Nampt-
mediated systemic NAD biosynthesis is critical
for b cell function, suggesting a vital framework
for the regulation of glucose homeostasis.
INTRODUCTION
Nicotinamide adenine dinucleotide (NAD) and its deriva-
tive compounds are essential coenzymes in cellular redox
reactions in all living organisms. NAD also participates in
a number of important signaling pathways in mammalian
cells, including mono- and poly-ADP-ribosylation and
synthesis of cyclic ADP-ribose and nicotinate adenineCell Mdinucleotide phosphate (Belenky et al., 2007; Rongvaux
et al., 2003). Recently, it has also been demonstrated
that NAD and its derivatives play an important role in tran-
scriptional regulation (Denu, 2003; Lin and Guarente,
2003). In particular, the discovery that the evolutionarily
conserved Sir2 family catalyzes protein deacetylation in
an NAD-dependent manner (Imai et al., 2000; Landry
et al., 2000; Smith et al., 2000) has drawn much attention
to this novel role for NAD. Despite the importance of NAD
in these biological events, the regulation of NAD biosyn-
thesis in vertebrates remains poorly understood.
In prokaryotes and lower eukaryotes, such as yeast,
NAD is synthesized by the de novo pathway via quinolinic
acid and by the salvage pathway via nicotinic acid (Be-
lenky et al., 2007; Revollo et al., 2007; Rongvaux et al.,
2003) (see Figure S1A in the Supplemental Data available
with this article online). In vertebrates, NAD biosynthesis is
markedly different from that in yeast and invertebrates.
Mammals predominantly use nicotinamide rather than
nicotinic acid as a precursor for NAD biosynthesis (Magni
et al., 1999). Instead of undergoing deamidation to nico-
tinic acid, nicotinamide is directly converted to nicotin-
amide mononucleotide (NMN) by nicotinamide phospho-
ribosyltransferase (Nampt) (Figures S1B and S1C). NMN
is then converted to NAD by nicotinamide/nicotinic acid
mononucleotide adenylyltransferase (Nmnat).
Nampt has ancient origins as an NAD biosynthetic en-
zyme. It was originally identified as the product of the
NadV gene in Haemophilus ducreyi (Martin et al., 2001)
and has been found even in some bacteriophages (Miller
et al., 2003). The homology of Nampt proteins between
bacteriophages, bacteria, and vertebrates is unusually
high (Revollo et al., 2004; Rongvaux et al., 2003). We
and other groups have characterized the biochemical na-
ture of mammalian Nampt (Revollo et al., 2004; Rongvaux
et al., 2002; van der Veer et al., 2005). We haveetabolism 6, 363–375, November 2007 ª2007 Elsevier Inc. 363
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NAD biosynthetic pathway from nicotinamide and regu-
lates the activity of the NAD-dependent deacetylase
Sirt1 in mammalian cells (Revollo et al., 2004). Further-
more, we and other groups have recently determined
crystal structures of the Nampt apoenzyme, the Nampt-
NMN complex, and the complex of Nampt and its potent
chemical inhibitor FK866 (Khan et al., 2006; Kim et al.,
2006; Wang et al., 2006), demonstrating that this enzyme
is a dimeric type II phosphoribosyltransferase. These
studies have firmly established the biochemical and struc-
tural basis of Nampt as an NAD biosynthetic enzyme.
Interestingly, the gene encoding human Nampt was
originally isolated as a presumptive cytokine named pre-
B cell colony-enhancing factor (PBEF) that enhances the
maturation of B cell precursors in the presence of interleu-
kin-7 (IL-7) and stem cell factor (SCF) (Samal et al., 1994).
Although this function of PBEF has not been reconfirmed
to date, several groups have since reported a cytokine-like
function of PBEF (Jia et al., 2004; Moschen et al., 2007;
Ognjanovic andBryant-Greenwood, 2002; Ye et al., 2005).
Additionally, Nampt/PBEF has recently been reidentified
as a ‘‘new visceral fat-derived hormone’’ named visfatin
(Fukuhara et al., 2005). Strikingly, visfatin was reported
to exert insulin-mimetic effects in cultured cells and to
lower plasma glucose levels in mice by binding to and
activating the insulin receptor. However, the physiological
relevance of visfatin remains controversial (Arner, 2006;
Revollo et al., 2007; Sethi, 2007; Stephens and Vidal-Puig,
2006). Subsequent studies have produced conflicting re-
sults regarding a possible connection of visfatin to obesity,
type 2 diabetes, and other metabolic complications (for
review, see Sethi, 2007; Stephens and Vidal-Puig, 2006).
Additionally, because this protein lacks a signal sequence
for secretion, it has been suggested that the presence of
Nampt/PBEF/visfatin in extracellular compartments might
be simply due to either cell lysis or cell death (Hug and
Lodish, 2005; Stephens and Vidal-Puig, 2006).
Herewe show that Nampt/PBEF/visfatin functions as an
intra- and extracellular NAD biosynthetic enzyme. There-
fore, we will refer to this protein primarily as Nampt
throughout the rest of this paper. The extracellular form
of Nampt (eNampt), which is positively secreted through
a nonclassical secretory pathway, does not show insu-
lin-mimetic effects in vitro or in vivo but rather exhibits
robust, even higher, NAD biosynthetic activity compared
to its intracellular form (iNampt). Nampt-deficient hetero-
zygous (Nampt+/) female mice show moderately im-
paired glucose tolerance and reduced glucose-stimulated
insulin secretion (GSIS). Consistent with this in vivo phe-
notype, primary islets isolated from Nampt+/ mice show
significant decreases in NAD biosynthesis and insulin se-
cretion in response to glucose. A similar phenotype is also
observed in wild-type primary islets treated with FK866.
These defects in NAD biosynthesis and GSIS can be
corrected by the administration of the Nampt reaction
product NMN in vivo and in vitro, demonstrating that the
observed defects are due to the lack of the NAD biosyn-
thetic activity of Nampt. Strikingly, a high concentration364 Cell Metabolism 6, 363–375, November 2007 ª2007 Elseviof NMN is found in mouse plasma, and plasma eNampt
and NMN levels are reduced in Nampt+/ females. These
findings strongly suggest that Nampt-mediated systemic
NAD biosynthesis plays a critical role in the regulation of
b cell function, providing important insights toward devel-
oping preventive/therapeutic interventions against meta-
bolic complications such as type 2 diabetes.
RESULTS
Nampt Is Highly Expressed in Brown Adipose
Tissue, Liver, Kidney, and Heart in Mice
It has been shown that Nampt has both intra- and extra-
cellular forms in mammals, but their physiological func-
tions have been the matter of debate (Revollo et al.,
2007). To elucidate the physiological role of Nampt, we
first surveyed the tissue distribution of iNampt in mice
(Figure 1A). Among the tissues examined, brown adipose
tissue (BAT), liver, and kidney showed the highest levels of
iNampt protein expression, and heart showed an interme-
diate level of iNampt. White adipose tissue (WAT), lung,
spleen, testis, and muscle showed low levels of iNampt,
and levels of iNampt in the brain and pancreas were unde-
tectable. These findings suggest that the requirement of
Nampt-mediated NAD biosynthesis might vary widely
among different tissues.
Differentiated Adipocytes Produce eNampt
Because Nampt has been reported to act as an adipokine
(Fukuhara et al., 2005), we examined the production of in-
tra- and extracellular Nampt by brown and white adipo-
cytes. We compared iNampt and eNampt levels between
the mouse preadipocyte cell lines HIB-1B and 3T3-L1,
which can differentiate into brown and white adipocytes,
respectively. iNampt was highly induced during the differ-
entiation of HIB-1B cells (Figure 1B, upper panel). In par-
allel with this induction, we also detected increasing
amounts of eNampt from day 2 to day 8 in HIB-1B condi-
tioned medium (Figure 1B, lower panel). This immunode-
tectable eNampt was purified from HIB-1B conditioned
medium, and its physical identity was confirmed by tan-
dem mass spectrometric peptide analyses (data not
shown). We estimated that the concentration of eNampt
in HIB-1B conditioned medium at day 8 was 100 ng/ml
(data not shown), a concentration comparable to that of
adiponectin in 24 hr culture supernatants of differentiated
human adipocytes (Wang et al., 2005). During the differen-
tiation of 3T3-L1 white preadipocytes, a similar induction
of iNampt was detected, although the final induction level
of iNampt in differentiated 3T3-L1 cells was significantly
lower than that in differentiated HIB-1B cells (Figure 1C,
upper panel). A very low level of eNampt was detectable
in 3T3-L1 conditioned medium at day 8 after concentra-
tion (Figure 1C, middle and lower panels). iNampt pro-
tein levels also increased mildly during the differentiation
of human SGBS white preadipocytes (Figure 1D, left
panel). eNampt was detectable in concentrated SGBS
conditioned medium at day 8 when SGBS cells fully dif-
ferentiated and started secreting adiponectin (Figure 1D,er Inc.
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lular Nampt in Mice and Production of
Intra- and Extracellular Nampt during
Adipocyte Differentiation
(A) Distribution of intracellular Nampt (iNampt)
inmouse tissues. 22.5 mg of each tissue extract
from a C57BL/6 mouse was analyzed by west-
ern blotting with Nampt- and actin-specific
antibodies; 5 mg of cell extract from a Nampt-
overexpressing NIH 3T3 cell line (Nampt1)
was loaded as a reference. WAT, white adi-
pose tissue; BAT, brown adipose tissue.
(B) Production of intra- and extracellular Nampt
(iNampt and eNampt) during differentiation of
HIB-1B brown preadipocytes. Upper panel:
Confluent cultures of HIB-1B cells were differ-
entiated, and cell extracts were prepared at the
indicated days. Forty-five micrograms of each
cell extract was analyzed. Lower panel: 20 ml
of each culture supernatant collected at the
indicated days was analyzed.
(C) Production of iNampt and eNampt during
differentiation of 3T3-L1 white preadipocytes.
Upper panel: 45 mg of each cell extract col-
lected at the indicated days was analyzed.
Middle panel: 20 ml of culture supernatant
was analyzed. Lower panel: Concentrated
culture supernatant was analyzed at day 8
to detect eNampt. Ten micrograms of cell ex-
tract from Nampt-overexpressing fibroblasts
(Nampt1) was loaded as a reference in each
experiment.
(D) Production of iNampt and eNampt during
differentiation of human SGBSwhite preadipo-
cytes. Left and middle panels: 13 mg of each
cell extract and 25 ml of each culture superna-
tant (10-fold concentrated) collected at the
indicated points were analyzed. Adiponectin
production is also shown as a positive control
for adipocyte differentiation. Pre, undifferenti-
ated preadipocytes; d4, differentiating adipo-
cytes at day 4; d8, mature adipocytes; CM,
control medium; SN, supernatant. Right panel:
iNampt protein expression was analyzed in
tissue extracts from human subcutaneous
(sc) and visceral (visc) WAT.middle panel). iNampt protein expression was also con-
firmed in human subcutaneous and visceral WAT extracts
(Figure 1D, right panel).
We further examined whether other cell types are capa-
ble of producing eNampt. We examined NIH 3T3 (a mouse
fibroblast cell line), HEK293 (a human embryonic kidney cell
line), Hepa1-6 (a mouse hepatocyte cell line), COS-7 (a
SV40-transformed monkey kidney cell line), and chinese
hamster ovary (CHO) cells. None of these cell lines naturally
produced eNampt; however, detectable amounts of
eNampt were observed in conditioned media from COS-7
and CHO cells when Nampt was highly overexpressed
(data not shown). Thus, eNampt is produced in a cell-
type-dependent manner, suggesting that eNampt secre-
tion is a highly regulated process. In this regard, HIB-1B
cells, which can produce high levels of both iNampt and
eNampt, provide a useful, robust culture system to further
investigate the production and function of eNampt.Cell MeeNampt Is Positively Secreted through
a Nonclassical Secretory Pathway
It has been speculated that the apparent ‘‘secretion’’ of
eNamptmight be simply due to either cell lysis or cell death
(Hug and Lodish, 2005; Stephens and Vidal-Puig, 2006).
We therefore investigated whether the production of
eNampt is due to positive secretion or to cell lysis/death.
We constructed C-terminally FLAG-tagged versions of
Nampt (Nampt-FLAG) as well as dihydrofolate reductase
(Dhfr) and preprolactin (Ppl) as controls for intracellular
and extracellular proteins, respectively (Dhfr-FLAG and
Ppl-FLAG). HIB-1B cell lines that stably expressed these
FLAG-tagged proteins were established and differenti-
ated. Dhfr-FLAG was detected exclusively in cell extracts
(Figure S2A), whereas prolactin-FLAG (Prl-FLAG) was de-
tected predominantly in supernatants (Figure S2B). Signif-
icant levels of Nampt-FLAG were detected in both cell ex-
tracts and supernatants in these cell lines, demonstratingtabolism 6, 363–375, November 2007 ª2007 Elsevier Inc. 365
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tiated HIB-1B Brown Adipocytes Has
High Nampt Enzymatic Activity
(A) eNampt-FLAG coimmunoprecipitates with
untagged eNampt from culture supernatants.
The eNampt-FLAG protein was immunopre-
cipitated with an anti-FLAG antibody from
8 ml of each culture supernatant and blotted
with either the same antibody or an anti-Nampt
antibody. The culture supernatants of the vec-
tor-transfected cells were used as a control.
(B) eNampt-FLAG protein immunoprecipitated
from culture supernatants of differentiated
Nampt-FLAG HIB-1B cells has Nampt enzy-
matic activity. Results are presented as mean
± SEM (n = 3).
(C) The kcat values of bacterially produced His-
tagged recombinant Nampt and intra- and
extracellular Nampt-FLAG from NIH 3T3 cells
and differentiated HIB-1B cells were calcu-
lated by measuring nicotinamide mononucleo-
tide (NMN) synthesis and quantifying the
amount of Nampt by western blotting (data
not shown). Results are presented as mean ±
SEM (n = 7 for His-tagged Nampt, 3 for iNampt
from NIH 3T3, 6 for iNampt from HIB-1B, and 4
for eNampt from HIB-1B); all differences in
pairwise comparisons are statistically signifi-
cant by Student’s t test (p < 0.05).that the presence of eNampt in supernatants is not due to
cell lysis or cell death. We also treated these cell lines with
brefeldin A (BFA), an inhibitor of protein secretion through
the Golgi-ER system. While eNampt-FLAG levels in the
supernatant were not affected by BFA, the secretion of
Prl-FLAG was significantly inhibited by BFA (Figure S2C).
This finding suggests that eNampt is not secreted through
aclassicalGolgi-ERsystembut rather through anonclassi-
cal secretory pathway. We achieved similar results by
transfecting CHO cells with each of the FLAG-tagged con-
structs (data not shown). These results demonstrate that
specific cell types (adipocytes and CHO cells) positively
secreteeNampt throughanonclassical secretorypathway.
eNampt Produced by Differentiated Adipocytes
Is Enzymatically Active
Using differentiated HIB-1B brown adipocytes as a model
system, we next analyzed the enzymatic activities of
iNampt and eNampt. Interestingly, we noticed that un-
tagged eNampt coimmunoprecipitated with eNampt-
FLAG (Figure 2A), indicating that eNampt forms a dimer,
as observed in the crystal structure (Wang et al., 2006).
The dimer formation of Nampt was also confirmed as an
100 kDa peak by size exclusion chromatography
(Figure S3). To examine whether dimerization is necessary
for Nampt enzymatic activity, we mutated Ser199 and
Ser200, both of which play key roles in forming a symmet-
rical dimer interface (Wang et al., 2006; Figure S3A), to
aspartic acid. The S199D and S200D Nampt mutants do
not dimerize properly and show decreased enzymatic
activity (Figure S3B; Table S1), suggesting that dimeriza-
tion is important for Nampt enzymatic activity.366 Cell Metabolism 6, 363–375, November 2007 ª2007 ElseviThe immunoprecipitates from the HIB-1B culture super-
natants were subjected to enzyme-coupled fluorometric
assays (Revollo et al., 2004) to compare the enzymatic
activities of iNampt and eNampt. The immunoprecipitated
eNampt-FLAG protein exhibited robust activity, while im-
munoprecipitates from culture supernatants of the back-
bone vector-transfected HIB-1B cells showed no activity
(Figure 2B). We also measured the Nampt enzymatic
activity of the bacterially produced recombinant Nampt
and the iNampt-FLAG immunoprecipitated from HIB-1B
and NIH 3T3 cellular extracts and calculated their kcat
values. Surprisingly, the eNampt-FLAG secreted from dif-
ferentiated HIB-1B cells showed a significantly higher kcat
value (0.380/s) than recombinant Nampt (0.035/s, 11-
fold increase), iNampt-FLAG from NIH 3T3 cells (0.082/s,
5-fold increase), and iNampt-FLAG from differentiated
HIB-1B cells (0.182/s,2-fold increase) (Figure 2C). Taken
together, our findings provide strong evidence that Nampt
functionsboth intra- andextracellularly asa robust, dimeric
NAD biosynthetic enzyme.
eNampt Does Not Exert Insulin-Mimetic Effects
In Vitro and In Vivo
Fukuhara et al. (2005) have reported that the same pro-
tein, renamed visfatin, exerts insulin-mimetic effects on
cultured cells by binding to and activating the insulin re-
ceptor. Therefore, we examined whether eNampt/visfatin
indeed exerts insulin-like effects.
We first investigated the potency of exogenously
administered Nampt/visfatin (eNampt/visfatin) to induce
adipocyte differentiation in the humanSGBSpreadipocyte
cell line. While SGBS preadipocytes fully differentiateder Inc.
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we did not detect differentiation into mature adipocytes
with equimolar concentrations of eNampt/visfatin (Fig-
ure 3A). Additionally, eNampt/visfatin proteins produced
in both bacteria and mammalian cells failed to mimic insu-
lin’s ability to induce expression of adipocyte differentia-
tion markers such as adiponectin and PPARg (Figure 3B).
We also examined whether eNampt/visfatin can enhance
glucose uptake in differentiated human SGBS and mouse
3T3-L1 adipocytes. While insulin shows dose-dependent
stimulation of glucose uptake, 100 nM eNampt/visfatin
did not show any effect on glucose uptake in differentiated
adipocytes (Figure 3C).
Because we were unable to reproduce the reported
insulin-mimetic activity of visfatin for adipogenesis and
glucose uptake, we next examined whether eNampt/
visfatin could induce insulin signaling. In this experiment,
weemployedseveraldifferentcellmodels: thehumanSGBS
cell line; the mouse 3T3-L1 cell line that was also used in
the original report of visfatin (Fukuhara et al., 2005); and
R- and R-IR cells, mouse fibroblast cell lines in which
the endogenous insulin-like growth factor 1 (IGF-1) recep-
tor is disrupted (R-) but the human insulin receptor is sta-
bly overexpressed (R-IR) (Miura et al., 1995). Although
insulin (10 nM) induced significant phosphorylation of the
insulin receptor and the downstream signaling kinase Akt
in each of these cell lines, equimolar concentrations of
eNampt/visfatin failed to induce phosphorylation of either
the insulin receptor or Akt (Figure 3D; Figure S4A). The
dose-dependent phosphorylation of the insulin receptor
was also observed in R-IR cells with 1–100 nM insulin,
but 10 and 100 nM eNampt/visfatin were unable to induce
phosphorylation in these cells (Figure 3E). Additionally,
conditionedmedia prepared from either control or Nampt-
overexpressing COS-7 cells did not induce phosphoryla-
tion of the insulin receptor or Akt (Figure S4B).
We also examined whether eNampt/visfatin reduces
blood glucose levels in vivo. Consistent with our results
from cell culture experiments, we were unable to detect
any immediate decrease in blood glucose levels even
when very high doses (i.e., 20-fold higher than previously
reported) of recombinant Nampt were injected (Fig-
ure S4C). Thus, in contrast to the original report of visfatin
(Fukuhara et al., 2005), we were unable to reproduce the
insulin-mimetic function of visfatin for adipogenesis, glu-
cose uptake, insulin signaling, or blood glucose reduction.
Nampt+/ Mice Show Impaired Glucose Tolerance
and Reduced Glucose-Stimulated Insulin
Secretion
To further elucidate the physiological role of Nampt, we
generated Nampt-deficient mice using a 129/Ola ES cell
line designated RRT307 created by the BayGenomics
consortium (currently a part of the International Gene Trap
Consortium; http://www.genetrap.org). In the RRT307 ES
cell line, theNampt gene locus is disrupted by the insertion
of a b-galactosidase/neomycin (b-geo) exon-trap vector
between exon 8 and exon 9. As a result of this insertion,
the C-terminal 128 amino acids are truncated and anCell M190 kDa fusion protein of Nampt and b-geo is produced.
Because the deleted residues include critical amino acids
that contribute to the Nampt catalytic site, such as Gly384
and Arg392 (Wang et al., 2006), this fusion protein is
expected to be enzymatically deficient. Consistent with
this notion, mice homozygous for the Namptmutant allele
died prior to embryonic day 10.5 (data not shown). Nampt
heterozygous (Nampt+/) mice were overtly normal but
showedsignificant decreases in iNampt levels in all tissues
examined (heart, liver, kidney, and BAT) and expressed
the Nampt-b-geo fusion protein (Figures S5A–S5D). We
also measured total NAD levels in BAT and liver from
Nampt+/ and control mice (Figure S5E). While NAD levels
were significantly decreased to 66% of control in
Nampt+/ BAT, no significant difference was observed in
NAD levels betweenNampt+/ and control livers. This pre-
sumably reflects the strong contribution of the tryptophan-
kynurenine pathway to de novo NAD biosynthesis in the
liver (Magni et al., 2004). Interestingly, female Nampt+/
mice showed a significant decrease in plasma eNampt
levels (50% of control eNampt levels), consistent with
adecrease in tissue iNampt levels,while a similar decrease
was not observed in Nampt+/ males (Figure S5F).
Both male and female Nampt+/ mice showed normal
body weight and mostly normal fed and fasted glucose
levels (Figures 4A and 4B). Nampt+/ and control mice did
not differ significantly in percent islet area or islet morphol-
ogy (Figures S6A and S6B). However, Nampt+/ female
mice showed moderately impaired glucose tolerance dur-
ing intraperitoneal glucose tolerance tests (i.p. GTTs) as
compared to control mice (Figure 4C), while males did not
show this phenotype (Figures S6C and S6D). We also
measured plasma insulin levels in female Nampt+/ and
control mice during i.p. GTTs.Nampt+/mice showed sig-
nificant decreases in insulin secretion at 15 and 30 min
after glucose injection compared to control littermates,
consistent with the i.p. GTT results (Figure 4D). We also
conducted insulin tolerance tests on these female mice,
but no difference was detected between Nampt+/ and
control mice (Figure 4E). These results suggest that
Nampt haplodeficiency significantly affects GSIS in pan-
creatic b cells and causes impaired glucose tolerance in
mice.
To confirm these in vivo results, we also examined GSIS
in isolatedprimary islets.Wild-typeprimary islets hada low
level of iNampt protein expression (10-fold lower than
liver), andNampt+/ islets exhibited a significant decrease
in iNampt expression (Figures S6E and S6F). Because
Nampt has a KM of 0.92 mM for nicotinamide (Revollo
et al., 2004), which falls within the physiological range of
plasma nicotinamide concentrations in mammals (Revollo
et al., 2007), we cultured isolated primary islets overnight
in RPMI medium containing 1 mM nicotinamide prior to
insulin secretion experiments. Under this experimental
condition, primary islets isolated from Nampt+/ female
mice showed an 40% decrease in NAD levels and a
comparable decrease in GSIS compared to those from
wild-type littermates (Figures 4F and 4G). Therefore, con-
sistent with the in vivo results, these findings support theetabolism 6, 363–375, November 2007 ª2007 Elsevier Inc. 367
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Systemic NAD Biosynthesis and b Cell FunctionFigure 3. eNampt Does Not Exert Insulin-Mimetic Effects on Adipogenesis, Glucose Uptake, or Insulin Signaling in Cultured Cells
(A) Differentiation of human SGBS preadipocytes was induced over a period of 8 days in standard inductionmedium containing 20 nM insulin or 20 nM
eNampt/visfatin. As a negative control, cells were treated in induction medium without insulin. Mature adipocytes were stained with Sudan III to
visualize lipid accumulation at day 8.
(B) mRNA expression levels of two adipocyte differentiation markers, adiponectin and PPARg, were analyzed by real-time quantitative RT-PCR.
SGBS preadipocytes were differentiated in standard induction medium with 20 nM insulin (3FC) or eNampt/visfatin proteins produced in bacteria
(P) or in mammalian cells (E) at the concentrations indicated.
(C) Differentiated SGBS and 3T3-L1 adipocytes were incubated with increasing concentrations of insulin or 100 nM eNampt/visfatin produced in
mammalian cells. Glucose uptake was determined using [14C]2-deoxyglucose at 0.5 mCi/ml for 5 min. Experiments were performed in quadruplicate,
and glucose uptake was normalized to the amount of protein. Basal glucose uptake in nonstimulated cells was set as 1.
(D) The effect of eNampt/visfatin on phosphorylation of the insulin receptor (InsR, upper panels) and Akt/PKB kinase (Akt, lower panels) was examined
in undifferentiated and differentiated human SGBS and mouse 3T3-L1 cells. Cells were starved overnight and then exposed to serum-free medium368 Cell Metabolism 6, 363–375, November 2007 ª2007 Elsevier Inc.
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ately Impaired Glucose Tolerance and
Reduced Glucose-Stimulated Insulin
Secretion
(A) Body weight of Nampt+/ and wild-type
(+/+) littermates at 8 weeks of age (n = 7–15).
(B) Fed and fasted glucose levels in male (M)
and female (F) Nampt+/ and control mice
(n = 10–18).
(C) Intraperitoneal glucose tolerance tests (i.p.
GTTs). Nampt+/ (n = 13) and control (n = 18)
females were injected with PBS and fasted
for 12–14 hr. Dextrose (3 g/kg body weight)
was injected intraperitoneally, and blood glu-
cose levels were measured.
(D) Plasma insulin levels in Nampt+/ and con-
trol female littermates at 0, 15, and 30 min time
points in i.p. GTTs. (n = 14 and 17 for Nampt+/
and control mice, respectively, for 0 and 30min
time points; n = 7 and 11 forNampt+/ and con-
trol mice, respectively, for 15 min time point.)
(E) Insulin tolerance tests. Nampt+/ (n = 9) and
control (n = 13) females were injected with
human insulin (0.75 U/kg body weight) after
fasting for 4 hr, and blood glucose levels
were measured.
(F) Nicotinamide adenine dinucleotide (NAD)
levels (pmol) in primary islets isolated from
Nampt+/ and control female mice. NAD levels
were measured by HPLC in duplicates of pri-
mary islets pooled from three individual mice
of each genotype.
(G) Insulin secretion (ng/ml/hr) from Nampt+/
and control islets at the indicated glucose con-
centrations (n = 4mice for each genotype). Iso-
lated primary islets were cultured overnight in
RPMI medium containing 1 mM nicotinamide
prior to insulin secretion experiments.
All results are expressed as mean ± SEM. *p%
0.05, **p% 0.01, ***p% 0.001.notion that Nampt haplodeficiency causes defects in NAD
biosynthesis and GSIS in pancreatic b cells.
The Defects in Nampt+/ Mice and Islets Can Be
Corrected by Administering NMN
If the glucose intolerance observed in Nampt+/ female
mice is indeed due to a lack of the NAD biosynthetic activ-
ity of Nampt, administration of NMN, a product of the
Nampt enzymatic reaction, might be able to correct their
defects. To test this possibility, we used the same
Nampt+/ and control female cohorts used for the previous
i.p. GTTs (see Figure 4C) and injected them intraperitone-
ally with NMN (500 mg/kg body weight)14 hr prior to i.p.
GTTs. Interestingly, after NMN administration, there was
no difference in blood glucose levels in i.p. GTTs between
Nampt+/ and control female mice (Figure 5A). In addition,Cell MeNMN-treated Nampt+/ and control mice also had similar
plasma insulin levels at each time point (Figure 5B). These
data clearly indicate that NMN administration corrects the
defect in GSIS observed inNampt+/mice.We also exam-
ined the effect of NMN on GSIS in primary islets isolated
fromNampt+/ and control female mice that were cultured
overnight in RPMI medium containing 1 mM nicotinamide
and 50 mM NMN. The addition of NMN significantly aug-
mented insulin secretion in response to 20 mM glucose
in both Nampt+/ and control islets, and after NMN treat-
ment, GSIS did not differ between Nampt+/ and control
islets (Figure 5C). These results strongly indicate that
the defects observed in Nampt+/ mice and islets are
due not to a lack of the insulin-mimetic activity of visfatin
but rather to a lack of the NAD biosynthetic activity of
Nampt.(SFM), 10 nM insulin (Ins), or 10 nM eNampt/visfatin produced in bacteria (P) or in mammalian cells (E). Signals of phosphorylated proteins were
normalized to those of nonphosphorylated proteins, and values are shown relative to the signal in serum-free medium (nR 3).
(E) Insulin receptor phosphorylation was examined in R-IR cells treatedwith different concentrations of insulin and eNampt/visfatin. Cells were treated
with the indicated concentrations of insulin, eNampt/visfatin produced in mammalian cells, or both (10 nM each). InsR was immunoprecipitated
with the anti-InsR antibody 29B4 and blotted with an anti-pan-phosphotyrosine antibody (upper panel). The membrane was reprobed with another
anti-InsR antibody, C19 (lower panel).
All results are expressed as mean ± SEM.tabolism 6, 363–375, November 2007 ª2007 Elsevier Inc. 369
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rates the Defects in Nampt+/ Mice and
Islets
(A) i.p. GTTs after NMN administration. The
same Nampt+/ (n = 18) and control (n = 19)
cohorts that were used for the i.p. GTTs in
Figure 4C were injected with NMN (500 mg/kg
body weight) 14 hr prior to i.p. GTTs.
(B) Plasma insulin levels in Nampt+/ and con-
trol female littermates at 0, 15, and 30 min time
points in i.p. GTTs. (n = 16 and 17 for Nampt+/
and control mice, respectively, for 0 and 30min
time points; n = 10 and 8 forNampt+/ and con-
trol mice, respectively, for 15 min time point.)
(C) Insulin secretion (ng/ml/hr) from NMN-
treated Nampt+/ and control islets at the indi-
cated glucose concentrations (n = 4 mice for
each genotype). Isolated primary islets were
cultured overnight in RPMI medium containing
1 mM nicotinamide plus 50 mM NMN prior to
insulin secretion experiments.
(D) NAD levels (pmol) in wild-type primary islets
treated overnight with NMN, FK866, or a com-
bination of both at the indicated concentra-
tions. NAD levels were measured by HPLC in
triplicates of primary islets pooled from four
individual wild-type mice.
(E) Insulin secretion (ng/ml/hr) at the indicated
glucose concentrations from control, FK866-
treated, and FK866 + NMN-treated wild-type
primary islets. Experiments were conducted
in triplicates of primary islets pooled from four
individual mice cultured for 48 hr in RPMI
medium containing 1 mM nicotinamide and
the indicated compounds (10 nM for FK866
and 100 mM for NMN) prior to insulin secretion
experiments.
All results are expressed as mean ± SEM.
*p% 0.05, **p% 0.01, ***p% 0.001.To further confirm the effect of NMN on NAD biosynthe-
sis and insulin secretion, we measured NAD levels in pri-
mary islets cultured overnight with NMN and/or FK866,
a potent chemical inhibitor of Nampt (Hasmann and
Schemainda, 2003). While 50 mM NMN enhanced NAD
biosynthesis by30%, 10 nM FK866 inhibited it by80%
in primary islets (Figure 5D), suggesting that Nampt-
mediated NAD biosynthesis is critical for primary islets.
Interestingly, in the presence of FK866, the administration
of 50–100 mMNMN restored NAD levels in a dose-depen-
dent manner (Figure 5D). Therefore, primary islets are able
to use exogenous NMN to maintain normal levels of NAD.
GSIS was suppressed by 60% in primary islets after 48
hr of FK866 treatment, and 100 mMNMN increased insulin
secretion in FK866-treated primary islets above control
islets (Figure 5E). Taken together, these findings demon-
strate that administration of NMN ameliorates defects in
NAD biosynthesis and GSIS caused by Nampt haplodefi-
ciency or the Nampt inhibitor FK866 in vivo and in vitro.
NMN Circulates Systemically In Blood
eNampt has been reported to be present in human and
mouse plasma (Sethi, 2007; Stephens and Vidal-Puig,
2006), and we confirmed this observation by western blot-370 Cell Metabolism 6, 363–375, November 2007 ª2007 Elsevting (Figure S5F). The high NAD biosynthetic activity of
eNampt suggests that it might synthesize NMN in blood
circulation. Therefore, we tested whether we could detect
NMN in mouse plasma by high-pressure liquid chroma-
tography (HPLC). Interestingly, mouse plasma extracts
showed a sharp peak at the same elution time as that of
standard NMN (Figure 6A). To confirm its identity, we
spiked mouse plasma extracts with 100 pmol of NMN
and found that the peak of interest was significantly in-
creased (Figure 6B). We also injected NMN (500 mg/kg
body weight) into mice and found that the peak of interest
increased significantly 15 min after NMN injection (Fig-
ure 6C), indicating that this particular peak represents
NMN. To further examine the nature of this peak, we col-
lected fractions that contained this peak and analyzed
them by ion-trap tandem mass spectrometry. Standard
NMN showed the signaturem/z of 335 and 123 (Figure 6D,
upper panel). The same signature spectra of NMN were
detected in the peak fractions from mouse plasma ex-
tracts (Figure 6D, lower panel), demonstrating that this
peak is indeed NMN.
We measured plasma NMN levels by HPLC and calcu-
lated its concentrations in control and Nampt+/ male and
female mice. Wild-type males and females had similarier Inc.
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Mouse Blood
(A) HPLC chromatograms of mouse plasma
extracts and standard NMN. Extracts that cor-
responded to 5 ml of plasma and standard
NMN were run in an isocratic condition at
a flow rate of 1 ml/min. The peak indicated
with an arrow shows the same elution time as
that of standard NMN.
(B) HPLC chromatograms of mouse plasma
extracts with or without a spike of 100 pmol
of NMN. Extracts that corresponded to 2.5 ml
of plasma were run at a flow rate of 0.7 ml/
min. The peaks indicated with arrows showed
a significant increase after the NMN spike.
(C) HPLC chromatograms of mouse plasma
extracts at 0 and 15 min time points after
NMN injection (500 mg/kg body weight). The
peaks indicated with arrows showed an in-
crease at the 15 min time point.
(D) Ion-trap tandem mass spectrometry analy-
sis for the fractions containing the peaks indi-
cated with arrows in the HPLC chromato-
grams. Upper panel, standard NMN; lower
panel, the peak fraction of a mouse plasma ex-
tract. The signature m/z of 123 (a) and 335 (b)
for NMN were detected in the peak fraction.
(E) Plasma NMN concentrations in control and
Nampt+/ male and female mice. Extracts cor-
responding to 2.5 ml of plasma were analyzed
by HPLC, and the NMN peaks were quanti-
tated for control (n = 3) and Nampt+/ (n = 4)
mice at 8 months of age. Results are ex-
pressed as mean ± SEM.plasma NMN concentrations (80–90 mM) (Figure 6E). Inter-
estingly, Nampt+/ females showed an 35% decrease
in plasma NMN concentrations compared to wild-type
littermates, whereas Nampt+/ males had values similar
to controls (Figure 6E). These sex-related differences are
consistent with the differences in plasma eNampt levels
between Nampt+/ males and females (Figure S5F). This
disparity in plasma eNampt and NMN levels between
genders is likely the cause of the i.p. GTT defects observed
only in Nampt+/ females. Taken together, these results
clearly demonstrate that NMN, the product of the Nampt
enzymatic reaction, circulates systemically in mammalian
blood.
DISCUSSION
Nampt/PBEF/Visfatin as an Intra- and
Extracellular NAD Biosynthetic Enzyme that
Regulates Pancreatic b Cell Function
In this study, we have provided several lines of evidence
demonstrating that Nampt functions as an intra- and
extracellular NAD biosynthetic enzyme and plays an im-
portant role in the regulation of GSIS in pancreatic b cells.Cell MFirst, fully differentiated mouse and human adipocytes
produce eNampt. eNampt is positively secreted through
a nonclassical secretory pathway, and the presence of
eNampt is not due to cell lysis or cell death. Second,
eNampt produced by differentiated adipocytes exhibits
robust NAD biosynthetic activity that is even higher than
iNampt, indicating that Nampt can function as an extracel-
lular enzyme. Third, eNampt does not have any insulin-
mimetic activity in vitro or in vivo. Fourth,Nampt+/ female
mice show impaired glucose tolerance and significantly
reduced insulin secretion in i.p. GTTs. Primary islets
isolated from Nampt+/ mice or treated with FK866 also
show significant decreases in NAD biosynthesis and insu-
lin secretion in response to glucose. Fifth, these defects in
NAD biosynthesis and GSIS can be corrected by the
exogenous administration of NMN in vivo and in vitro.
Finally, we have demonstrated that a high concentration
of NMN circulates systemically in mouse plasma. These
results reveal an important functional mode of Nampt as
an extracellular NAD biosynthetic enzyme and strongly
support the physiological significance of Nampt-mediated
systemic NAD biosynthesis in the regulation of b cell
function.etabolism 6, 363–375, November 2007 ª2007 Elsevier Inc. 371
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of Secreted eNampt
While the function of iNampt as an essential NAD biosyn-
thetic enzyme is well established (Revollo et al., 2004;
Rongvaux et al., 2002; van der Veer et al., 2005), the phys-
iological role of eNampt remains controversial. In this
study, we attempted to reproduce the reported insulin-
mimetic effects of eNampt/visfatin on adipogenesis, glu-
cose uptake, cellular insulin signaling, and blood glucose
levels in mice. Surprisingly, we were unable to obtain evi-
dence supporting the insulin-mimetic activity of eNampt/
visfatin. Furthermore, we found that Nampt+/ mice and
islets have defects in NMN/NAD biosynthesis and GSIS.
These defects are ameliorated by NMN administration in
Nampt+/ mice and islets. Thus, these findings strongly
indicate that the defects observed in Nampt+/ mice and
islets are due not to a lack of the proposed insulin-mimetic
activity of visfatin but to a lack of Nampt-catalyzed NMN
production. This conclusion is also supported by the find-
ings that the chemical inhibition of Nampt by FK866 also
causes defects in NAD biosynthesis and GSIS in primary
islets and that these defects are ameliorated by exoge-
nous NMN administration. Therefore, we conclude that
it is the NAD biosynthetic activity of Nampt, not the insu-
lin-mimetic activity of visfatin, that is physiologically
important for the regulation of glucose metabolism.
Cell-Type-Dependent Regulation of eNampt
Secretion
The fact that eNampt is positively secreted through a
nonclassical secretory pathway in a cell-type-dependent
manner indicates that the secretion of eNampt is a highly
regulated process. Because Nampt-FLAG has different
enzymatic activities dependent on the cell type and the
compartment, it is very likely that a posttranslational mod-
ification is responsible for one or both of the altered enzy-
matic activity and the secretion of eNampt. The treatment
of eNampt-FLAG from HIB-1B conditioned medium with
calf intestinal phosphatase and N-acetylglucosaminidase
did not change its enzymatic activity (data not shown), and
an extensive mass spectrometric search for the modifica-
tion has so far been unsuccessful. Further investigation
will be necessary to identify the presumed modification
of eNampt.
Interestingly, adipocytes apparently acquire the ability
to modify and secrete Nampt during their differentiation
process. Among the several cell types examined, only fully
differentiated adipocytes naturally produce eNampt.
Thus, it is conceivable that adipose tissue might be one
of the major sites of eNampt production in vivo. Under
normal physiological conditions, WAT does not appear
to produce high levels of iNampt and eNampt. However,
in certain pathophysiological conditions that cause signif-
icant changes in adipose tissue mass, structure, and/or
function, such as obesity and type 2 diabetes, WAT might
secrete more eNampt. Indeed, it has been reported that
circulating levels of eNampt are increased by hyperglyce-
mia (Haider et al., 2006b). Additionally, there are several
clinical studies reporting that higher plasma eNampt levels372 Cell Metabolism 6, 363–375, November 2007 ª2007 Elseviare associated with higher body mass index and percent
body fat (Berndt et al., 2005), type 2 diabetes (Chen
et al., 2006), and obesity in children (Haider et al., 2006a).
Therefore, it will be of great importance to identify the
stimuli that cause increasedproduction of eNampt inwhite
adipocytes in these pathophysiological conditions.
Nampt-Mediated Systemic NAD Biosynthesis
and Its Importance in the Regulation of Glucose
Metabolism
The findings that eNampt possesses robust NAD biosyn-
thetic activity and that 80–90 mMNMN circulates in mouse
plasma are striking, as it has been thought that NAD bio-
synthesis is an entirely intracellular process (Magni et al.,
1999; Rongvaux et al., 2003). Interestingly, only Nampt+/
females, but not males, have reduced plasma levels of
eNampt and NMN as well as defects in glucose metab-
olism. Although it is currently unclear why and how
Nampt+/ males maintain their plasma eNampt and
NMN levels, these results suggest that the maintenance
of high NMN levels by eNampt in blood circulation is crit-
ical for normal b cell function, probably because pancre-
atic islets have very low levels of iNampt compared to
other tissues. Furthermore, NMN concentrations in wild-
type mouse plasma are within the range that can enhance
and restore NAD biosynthesis and GSIS in normal and
FK866-treated primary islets in vitro, respectively. Based
on these findings, we propose that NMN functions as an
Figure 7. A Model for the Regulation of Insulin Secretion by
Nampt-Mediated Systemic NAD Biosynthesis in Pancreatic
b Cells
See text for details. eNampt, extracellular Nampt; iNampt, intracellular
Nampt; NMN, nicotinamide mononucleotide; Nmnat, nicotinamide/
nicotinic acid mononucleotide adenylyltransferase.er Inc.
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b cell function (Figure 7). Given that fully differentiated ad-
ipocytes are natural producers of eNampt, adipose tissue
may regulate b cell function through secretion of eNampt
and extracellular biosynthesis of NMN (Figure 7). Intrigu-
ingly, individuals homozygous for either of two single-
nucleotide polymorphism variants in the Nampt gene
promoter region have lower fasting plasma insulin levels
(Bailey et al., 2006). Therefore, circulating NMN levels,
maintained by plasma eNampt, may play an important
role in regulating b cell function in physiological and path-
ophysiological conditions. It will be of great interest to
measure eNampt activity and NMN levels in plasma sam-
ples from patients with obesity and/or type 2 diabetes by
developing high-throughput detection methods.
Although the molecular mechanism underlying attenu-
ated GSIS in Nampt+/ islets is still unclear, alterations in
NAD levels could alter activities of important enzymes in
metabolic pathways such as glycolysis or fatty acid oxida-
tion in pancreatic b cells (Figure 7). These changes in NAD
would also affect other NAD-dependent enzymes, such as
the NAD-dependent deacetylase Sirt1 or poly-ADP-ribose
polymerase (PARP) (Figure 7). Sirt1 is particularly interest-
ing in this regard because we have previously demon-
strated that it promotes GSIS in b cells using pancreatic
b cell-specific Sirt1-overexpressing (BESTO) mice (Moy-
nihan et al., 2005). Interestingly, the phenotypes observed
in BESTO mice are the opposite of those observed in
Nampt+/ mice. Furthermore, NMN administration can
also augment GSIS in aged BESTO mice (K.F.M. and
S.I., unpublished data), suggesting that Sirt1 is a down-
stream regulator in pancreatic b cells that responds to
alterations in systemic NAD biosynthesis. Although further
investigation will be necessary to test the model, the dis-
covery that Nampt-mediated systemic NAD biosynthesis
is a critical contributor to b cell function opens up impor-
tant avenues for the development of therapeutics to treat
metabolic diseases such as type 2 diabetes.
EXPERIMENTAL PROCEDURES
Detection of Intracellular Nampt in Tissues
Ad libitum-fed C57BL/6 mice aged 3–4 months were sacrificed by car-
bon dioxide asphyxiation. Organs were immediately collected, ho-
mogenized in 13 Laemmli SDS sample buffer, and boiled for 5 min.
Samples were then centrifuged at 20,000 3 g to remove debris, and
protein concentrations were measured by Bradford assay (Bio-Rad).
22.5 mg tissue extracts were analyzed by western blotting with a rabbit
polyclonal anti-Nampt antibody as described previously (Revollo et al.,
2004).
Differentiation of 3T3-L1, HIB-1B, and SGBS
Preadipocyte Cell Lines
All mouse cell lines were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and antibiotics.
Confluent cultures of HIB-1B brown preadipocytes were differentiated
by adding 5 mg/ml insulin, 0.5mM isobutylmethylxanthine (IBMX), 1 mM
dexamethasone, and 1 nM triiodothyronine (T3, Sigma) for 2 days and
then refeeding the medium containing 5 mg/ml insulin and 1 nM T3
every other day for 6 more days. 3T3-L1 white preadipocytes were
differentiated similarly, except that T3 was absent from the medium
throughout the entire differentiation process.Cell MeHuman SGBS preadipocytes (Wabitsch et al., 2001), kindly provided
by M. Wabitsch (University of Ulm, Germany), were grown and differ-
entiated into mature adipocytes as described previously (Ko¨rner
et al., 2005). Briefly, preadipocytes at confluence were exposed to
serum-free basal medium supplemented with 10 mg/ml apotransferrin,
20 nM human recombinant insulin, 10 nM hydrocortisone, and 0.2 nM
triiodothyroxine. For the first 4 days, this adipocyte culture medium
was additionally supplemented with 25 nM dexamethasone, 500 mM
IBMX, and 2 mM rosiglitazone.
iNampt and eNampt proteins were detected bywestern blotting with
whole-cell extracts or culture supernatants and anti-Nampt anti-
bodies. A rabbit polyclonal antibody (Revollo et al., 2004) and a mouse
monoclonal antibody (OMNI379, ALX-804-717, Axxora) were used for
these experiments.
Expression and Immunoprecipitation of Intra- and
Extracellular Nampt-FLAG
A C-terminally FLAG-tagged mouse Nampt (Nampt-FLAG) cDNA
was created with the following forward and reverse primers containing
EcoRI sites: forward, 50-TTAGAATTCAGCCCATTTTTCTCCTTGCT-30;
reverse, 50-AATGAATTCTACTTATCGTCGTCATCCTTGTAATCTCCTC
CATGAGGTGCCACGTCCTGCTCGATGTT-30. The resulting cDNA was
confirmedby sequencing. TheNampt-FLAGcDNAwas then cloned into
the mammalian expression vector pCXN2. To create HIB-1B cell lines
expressing Nampt-FLAG, HIB-1B cells were transfected with pCXN2-
Nampt-FLAG or pCXN2 and selected at 500 mg/ml of G418
(Invitrogen, CA) for 2 weeks.
For immunoprecipitation of intracellular Nampt-FLAG, whole-cell
extracts were prepared with ice-cold immunoprecipitation (IP) buffer
(phosphate-buffered saline [pH 7.4], 0.5% NP-40, 1 mM EDTA,
1 mM NaF, 10 mM trichostatin A, 10 mM nicotinamide, 0.5 mM DTT,
protease inhibitor cocktail [Roche]) and mixed with agarose beads
conjugated with mouse monoclonal M2 anti-FLAG antibody (F2426,
Sigma) for 3–4 hours at 4C. For immunoprecipitation of extracellular
Nampt-FLAG, HIB-1B culture supernatants were collected after incu-
bating differentiated HIB-1B cells overnight with DMEM without fetal
bovine serum but supplemented with 1 mg/ml insulin and 1 nM triiodo-
thyronine, filtered through a 0.22 mm PES membrane, concentrated
with Amicon Ultra-15 columns (Millipore), and mixed with anti-FLAG
beads for 3–4 hours at 4C. Immunoprecipitates were washed twice
with IP buffer and twice with PBS.
Enzymatic Reactions
Nampt enzymatic reactions were conducted as previously described
(Revollo et al., 2004). Briefly, immunoprecipitates on anti-FLAG beads
were incubated in enzymatic reaction buffer (50 mM Tris-HCl [pH 8.5],
100 mM NaCl, 0.25 mM nicotinamide, 10 mM MgSO4, 1.5% ethanol,
0.5 mM PRPP, 2.0 mM ATP) for 55 min at 37C. After this reaction,
mouse recombinant Nmnat and yeast alcohol dehydrogenase (Sigma)
were added at a final concentration of 10 mg/ml each, and the mixture
was incubated for 5 min at 37C. Supernatants were then collected by
spinning down anti-FLAG beads, and autofluorescence of NADH was
measured in a PerkinElmer LS 50B fluorometer (340 nm excitation,
460 nm emission). NADH autofluorescence values were converted to
the amounts of NMN using the standard curve drawn with known
amounts of NMN. Immunoprecipitates bound on anti-FLAG beads
were extracted with Laemmli sample buffer, boiled for 5 minutes,
and analyzed by western blotting with anti-Nampt antibodies. The
amounts of Nampt used for enzymatic reactions were quantitated
compared to the standards of mouse recombinant Nampt. kcat values
were calculated based on the molar amount of NMN generated per the
molar amount of immunoprecipitated Nampt-FLAG protein per unit
time.
eNampt Secretion Assays
C-terminally FLAG-tagged versions of mouse dihydrofolate reductase
(Dhfr, a gift from W. Yokoyama, Washington University) and bovine
preprolactin (Ppl, a gift from C. Nicchitta, Duke University) weretabolism 6, 363–375, November 2007 ª2007 Elsevier Inc. 373
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FLAG and pCXN2-Ppl-FLAG), respectively, and HIB-1B preadipocyte
cell lines stably expressing these proteins were generated.
HIB-1B cells expressing Nampt-FLAG, Dhfr-FLAG, and Ppl-FLAG
were differentiated as described above. To detect intracellular FLAG-
tagged proteins, cell extracts were collected and immunoprecipitated
as described above. To detect extracellular FLAG-tagged proteins,
culture supernatants (8 ml) were collected, immunoprecipitated
overnight at 4C with anti-FLAG antibody-conjugated beads, and
analyzed bywestern blottingwith rabbit polyclonal anti-FLAG antibody
(Sigma). For theBFAexperiment, cellswere treatedwithBFA (0.5mg/ml,
Sigma) for 12 hr.
CHO cells at 50%–60% confluency were transfected with pCXN2,
pCXN2-Dhfr-FLAG, pCXN2-Ppl-FLAG, or pCXN2-Nampt-FLAG. Cell
extracts and culture supernatants were collected 48 hr after transfec-
tion, subjected to immunoprecipitation with anti-FLAG antibody-
conjugated beads, and analyzed by western blotting as described
above.
Glucose and Insulin Measurements
Glucose levels were determined using an Accu-Chek II glucometer
(Roche Diagnostics) with blood collected from the tail vein. For deter-
mining insulin levels, blood was collected from the tail vein in chilled
heparinized capillary tubes, and plasma was separated by centrifuga-
tion and stored at 80C. Insulin levels were determined on 5–10 ml
aliquots using a rat insulin ELISA kit with mouse insulin standards
(ALPCO) at the Washington University RIA Core Facility.
Intraperitoneal Glucose Tolerance Tests and Insulin
Tolerance Tests
For i.p. GTTs, mice were injected with PBS or NMN (500 mg/kg body
weight) and fasted for 14 hrs; dextrose (3 g/kg body weight) was then
injected intraperitoneally; and blood glucose levels were measured at
0, 15, 30, 60, and 120 min after injection. Plasma was also collected at
0, 15, and 30 min time points after glucose injection and submitted to
the Washington University RIA Core Facility for insulin measurements.
For insulin tolerance tests, female mice were fasted for 4 hrs; human
insulin (0.75 U/kg body weight; Lilly) was injected intraperitoneally;
and blood glucose levels were measured at 0, 15, 30, 45, and 60 min
after insulin injection. All animal procedures were approved by the
Washington University Animal Studies Committee.
Glucose-Stimulated Insulin Secretion from Primary Islets
Islets were isolated by collagenase digestion as described previously
(Moynihan et al., 2005). Briefly, pancreata were inflated with isolation
buffer (103 HBSS, 10 mM HEPES, 1 mM MgCl2, 5 mM glucose [pH
7.4]) containing 0.375 mg/ml collagenase (Sigma) via the pancreatic
duct after clamping off its entry site to the duodenum. The inflated
pancreata were then removed, incubated at 37C for 12–15 min, and
shaken vigorously. Islets were separated from acinar tissue after a
series of washes and passages through a 70 mm nylon BD Falcon
Cell Strainer (BD Biosciences). Hand-picked islets were cultured over-
night in RPMI medium containing 1 mM nicotinamide, 5 mM glucose,
2 mM L-glutamine, penicillin/streptomycin, and 10% fetal bovine
serum. The islets were then preincubated in oxygenated Krebs-Ringer
bicarbonate (KRB) buffer (1 mM nicotinamide, 119 mM NaCl, 4.7 mM
KCl, 25 mM NaHCO3, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM
KH2PO4, and 0.25% radioimmunoassay-grade BSA) supplemented
with 2 mM glucose for 1 hr at 37C. Islets of similar size were hand
picked into groups of ten islets in triplicate and incubated with 1 ml
KRB buffer containing either 2 mM glucose or 20 mM glucose for 1
hr at 37C.
For treatments with NMN, FK866, or the combination of the two
compounds, primary islets were pooled from three or four wild-type
B6 mice and grouped for each experimental condition. Islets were cul-
tured overnight or for up to 48 hr in RPMI media containing 50–100 mM
NMN and/or 10 nM FK866 prior to insulin secretion experiments.374 Cell Metabolism 6, 363–375, November 2007 ª2007 ElseviStatistical Analyses
Statistical analyses were carried out using an unpaired Student’s t test.
All values are expressed as mean ± standard error of the mean (SEM).
Differenceswereconsidered tobestatistically significantwhenp%0.05.
For additional experimental procedures, see Supplemental Data.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, six figures, and one table and can be found
with this article online at http://www.cellmetabolism.org/cgi/content/
full/6/5/363/DC1/.
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